Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Lanoxin — LANOXICAPS
Application NDA018118 (NDA)
Isopto Carpine — OCUSERT PILO-40
Application NDA017548 (NDA)
Dyrenium — DYRENIUM
Application NDA013174 (NDA)
Isopto Carpine — OCUSERT PILO-20
Application NDA017431 (NDA)
Lanoxin — LANOXIN
Application NDA009330 (NDA)
Dibenzyline — DIBENZYLINE
Application NDA008708 (NDA)
Isopto Carpine — PILOPINE HS
Application NDA018796 (NDA)
Parnate — PARNATE
Application NDA012342 (NDA)
Isopto Carpine — SALAGEN
Application NDA020237 (NDA)
Nilandron — NILANDRON
Application NDA020169 (NDA)
Lanoxin — LANOXIN
Application NDA020405 (NDA)
Panretin — PANRETIN
Application NDA020886 (NDA)
Uroxatral — UROXATRAL
Application NDA021287 (NDA)
Lanoxin — DIGOXIN
Application NDA021648 (NDA)
Isopto Carpine — ISOPTO CARPINE
Application NDA200890 (NDA)
Isopto Carpine — VUITY
Application NDA214028 (NDA)
Isopto Carpine — QLOSI
Application NDA217836 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)